Search Press releases Keywords From To 16 Dec 2021 Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Ankylosing Spondylitis Trial Read More 10 Dec 2021 UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis Read More 3 Dec 2021 Disposals of own shares Read More 3 Dec 2021 UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021 reinforcing long-standing commitment to advancing epilepsy treatment and care Read More 2 Dec 2021 UCB Announces Global Partnership to Bring Disease-Modifying Therapies to People Living with Parkinson’s Disease Read More 30 Nov 2021 UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases Read More Pagination First page Previous page Previous … Page 44 Page 45 Page 46 Page 47 Current page 48 Page 49 Page 50 Page 51 Page 52 … Page 48 of 60 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
